Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
228
datasets available to search
ShareScore release 0.9.0
Dataset results
228 results for “Volumetric”
A Volumetric Nomogram for Height, Weight, and Intra Abdominal Volume
ClinicalTrials.gov study NCT04515485. IPD Sharing: NO. Countries: 0. Publications: 0.
A Novel Volumetric Analysis Using CAD/CAM Scanners in Gingival Recession Treatment
ClinicalTrials.gov study NCT03295604. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Correlation Between Maxillary Sinus (Linear and Volumetric Measurements) and Midface Width Using CBCT
ClinicalTrials.gov study NCT05847777. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Figure-of-Eight Hand, Volumetric Measurements and Reliability in Clinic With Hand Injured Patients
ClinicalTrials.gov study NCT03837951. IPD Sharing: NO. Countries: 0. Publications: 0.
Volumetric Changes in Large Cystic Lesions Using Active Decompression and Distraction Sugosteogenesis vs Passive Decompression
ClinicalTrials.gov study NCT06262802. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Sexual Dimorphism of Sphenoid and Maxillary Air Sinuses Via 3D Volumetric Segmentation of CBCT
ClinicalTrials.gov study NCT05907083. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Volumetric MRI Brain in Patients With Migraine
ClinicalTrials.gov study NCT06077448. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
ClinicalTrials.gov study NCT04780789. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Different Maxillary Sinus 3D Shapes Assessment Using CBCT Volumetric Segmentation
ClinicalTrials.gov study NCT05922410. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
ClinicalTrials.gov study NCT02889770. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Clinical and Volumetric Changes Following Single Pontic Site Development Using Multilayered Platelet Rich Fibrin Versus Connective Tissue Grafting in the Maxillary Esthetic Zone
ClinicalTrials.gov study NCT06926452. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Transcriptome profiling of the early response to volumetric muscle loss repair strategies
GEO Series GSE125896. Rattus norvegicus. 32 samples. Type: Expression profiling by high throughput sequencing.
Deconstruction of cellular dynamics after treatment of volumetric muscle loss injury with extracellular matrix
GEO Series GSE266585. Canis lupus familiaris. 17 samples. Type: Other.
Metabolic reprogramming of macrophages via engineered nanoparticles after volumetric muscle loss
GEO Series GSE288005. Mus musculus. 2 samples. Type: Expression profiling by high throughput sequencing.
Aberrant fibro-adipogenic progenitor subpopulations drive volumetric muscle loss-induced fibrosis
GEO Series GSE308267. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing; Other.
Spatiotemporal mapping of immune and stem cell dysregulation after volumetric muscle loss
GEO Series GSE205707. Canis lupus familiaris; Mus musculus. 18 samples. Type: Other.
Dataset related to article "Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience."
<p>INTRODUCTION:</p> <p>We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM) after lung-sparing surgery with pleurectomy and decortication.</p> <p>MATERIALS AND METHODS:</p> <p>Patients affected by MPM who had undergone pleurectomy and decortication and adjuvant radiotherapy with VMAT were included. The endpoints of the present analysis were local control, progression-free survival, and overall survival. Assessment of the variables affecting survival was performed using univariate and multivariate Cox proportional hazard models.</p> <p>RESULTS:</p> <p>A total of 49 patients were included in the present study. Of the 49 patients, 96% had been treated with a trimodality approach. Radiotherapy was delivered to a median dose of 44 Gy in 22 fractions (range, 22-59.4 Gy). The treatment was well tolerated, with just 2 grade 3 acute toxicities, 1 grade 5, and 2 grade 4 toxicities recorded during the follow-up period. The median follow-up period was 27.4 months. The local control rate at 12, 24, and 36 months was 75.2%, 67.4%, and 56.5%, respectively. The median progression-free survival was 14.9 months (95% confidence interval [CI], 7.5-25.2). The median overall survival was 21.5 months (95% CI, 15.3-37.1). On multivariate analysis, the administration of carboplatin- instead of cisplatin-based chemotherapy (hazard ratio, 2.97; 95% CI, 1.22-7.26; P = .017) and R2 resection (hazard ratio, 1.95; 95% CI, 1.27-2.99; P = .002) showed a negative correlation with overall survival. On univariate analysis, the percentage of the heart receiving >20 Gy and >30 was associated with the occurrence of late pneumonitis (P = .018 and P = .077).</p> <p>CONCLUSION:</p> <p>VMAT is feasible in the setting of MPM after lung-sparing surgery. The toxicity rates were reduced with this technique compared with historical data of older techniques. Local and distant failure remain a major issue to be addressed in future trials.</p>
Dataset related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"
<p>This record contains data related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"</p> <p>Abstract</p> <p><strong>Background: </strong> To investigate the role of intensity modulated proton therapy (IMPT) compared to volumetric modulated arc therapy (VMAT) for advanced supradiaphragmatic Hodgkin's lymphoma (HL) in young female patients by assessing dosimetric features and modelling the risk of treatment related complications and radiation-induced secondary malignancies.</p> <p><strong>Methods: </strong> A group of 20 cases (planned according to the involved-site approach) were retrospectively investigated in a comparative planning study. Intensity modulated proton plans (IMPT) were compared to VMAT RapidArc plans (RA). Estimates of toxicity were derived from normal tissue complication probability (NTCP) calculations with either the Lyman or the Poisson models for a number of endpoints. Estimates of the risk of secondary cancer induction were determined for lungs, breasts, esophagus and thyroid. A simple model-based selection strategy was considered as a feasibility proof for the individualized selection of patients suitable for proton therapy.</p> <p><strong>Results: </strong> IMPT and VMAT plans resulted equivalent in terms of target dose distributions, both were capable to ensure high coverage and homogeneity. In terms of conformality, IMPT resulted ~ 10% better than RA plans. Concerning organs at risk, IMPT data presented a systematic improvement (highly significant) over RA for all organs, particularly in the dose range up to 20Gy. This lead to a composite average reduction of NTCP of 2.90 ± 2.24 and a reduction of 0.26 ± 0.22 in the relative risk of cardiac failures. The excess absolute risk per 10,000 patients-years of secondary cancer induction was reduced, with IMPT, of 9.1 ± 3.2, 7.2 ± 3.7 for breast and lung compared to RA. The gain in EAR for thyroid and esophagus was lower than 1. Depending on the arbitrary thresholds applied, the selection rate for proton treatment would have ranged from 5 to 75%.</p> <p><strong>Conclusion: </strong> In relation to young female patients with advanced supradiaphragmatic HL, IMPT can in general offer improved dose-volume sparing of organs at risk leading to an anticipated lower risk of early or late treatment related toxicities. This would reflect also in significantly lower risk of secondary malignancies induction compared to advanced photon based techniques. Depending on the selection thresholds and with all the limits of a non-validated and very basic model, it can be anticipated that a significant fraction of patients might be suitable for proton treatments if all the risk factors would be accounted for.</p> <p> </p>
Dataset related to article "Automatic Planning of the Lower-Extremities for Total Marrow Irradiation Using Volumetric Modulated Arc Therapy"
<p>This record contains raw data related to article "Automatic Planning of the Lower-Extremities for Total Marrow Irradiation Using Volumetric Modulated Arc Therapy"</p> <p><strong>Abstract</strong></p> <p><strong>Purpose</strong>: Total marrow (and lymphoid) irradiation (TMI-TMLI) is limited by the couch travel range of modern linacs, which forces to split the treatment delivery into two plans with opposite orientations: a head-first supine upper-body plan, and a feet-first supine lower-extremities plan. A specific field junction is thus needed to obtain adequate target coverage in the overlap region of the two plans. In this study, an automatic procedure was developed for field junction creation and lower-extremities plan optimization.</p> <p><strong>Methods</strong>: Ten patients treated with TMI-TMLI at our institution were selected retrospectively. The planning of the lower-extremities was performed automatically. Target volume parameters (CTV_J-V<sub>98%</sub>>98%) at the junction region and several dose statistics (D<sub>98%</sub>, D<sub>mean</sub>, and D<sub>2%</sub>) were compared between automatic and manual plans. The Modulation Complexity Score (MCS) was used to assess plan complexity.</p> <p><strong>Results</strong>: The automatic procedure required 60-90 minutes, depending on the case. All automatic plans achieved clinically acceptable dosimetric results (CTV_J-V<sub>98%</sub>>98%), with significant differences found at the junction region, where D<sub>mean </sub>and D<sub>2% </sub>increased on average by 2.4% (p<0.03) and 3.0% (p<0.02), respectively. Similar plan complexity was observed (median MCS=0.12). Since March 2022 the automatic procedure has been introduced in our clinic, reducing the TMI-TMLI simulation-to-delivery schedule by 2 days.</p> <p><strong>Conclusions</strong>: The developed procedure allowed to streamline the treatment planning of TMI-TMLI, increasing efficiency and standardization, preventing human errors, while maintaining the dosimetric plan quality and complexity of manual plans. Automated strategies can simplify the future adoption and clinical implementation of TMI-TMLI treatments in new centers.</p> <p> </p>
Volumetric compression by heterogeneous scaffold embedding promotes cerebral organoid growth and maturation
GEO Series GSE242715. Homo sapiens. 5 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.